Naloxone Market, by Strength (2.0 mg/0.1 ml and 4.0 mg/ml, 1 mg/ml, 0.4 mg/ml, and Others), by Route of Administration (Intranasal, Intramuscular/Subcutaneous, and Intravenous), by Distribution Channel (Hospitals, (Public Hospitals and Private Hospitals),

Naloxone Market, by Strength (2.0 mg/0.1 ml and 4.0 mg/ml, 1 mg/ml, 0.4 mg/ml, and Others), by Route of Administration (Intranasal, Intramuscular/Subcutaneous, and Intravenous), by Distribution Channel (Hospitals, (Public Hospitals and Private Hospitals), Clinics (Including Addiction Clinics), Retail Pharmacies, Emergency Medical Services (EMS), Military Facilities, Miscellaneous Facilities, Online Pharmacies, and Others (long-term care facilities, etc.)), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)- Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030

Naloxone is available in two U.S. Food and Drug Administration (FDA) approved forms: injection and nasal spray. It is crucial to be educated on how and when to administer naloxone regardless of the type of medication being utilized. Those who are physically dependent on opioids may experience withdrawal symptoms minutes after receiving naloxone. Headaches, variations in blood pressure, a rapid heartbeat, sweating, nausea, vomiting, and tremors are examples of withdrawal symptoms. Although uncomfortable, this normally does not pose a life-threatening threat.

Market Dynamics

High prevalence of opioid overdose and increasing opioid crises in the U.S. are expected to fuel demand for naloxone in the region and thus, driving the market growth during the forecast period. For instance, according to the data published by the National Institute on Drug Abuse, 2021, U.S. federal government research institute, in the year 2019, about 50,000 people died from opioid-involved overdoses in the U.S. The addiction and misuse of opioids including heroin, synthetic opioids (fentanyl), and prescription pain relievers is a severe national crisis which affects social & economic welfare, and public health.

Market players are focused on product launches and approvals, which is expected to drive growth of the global naloxone market over the forecast period. For instance, in February 2019, Indivior Inc., a U.S. affiliate of Indivior Plc., launched an authorized generic version of SUBOXONE (naloxone and buprenorphine) sublingual film in the U.S. This authorized generic is being distributed and marketed on Indivior’s behalf by Sandoz Inc., one of the leading providers of generic pharmaceuticals and biosimilars.

Increasing initiatives by governments related to use and distribution of naloxone is expected to fuel growth of the global naloxone market. For instance, in February 2018, Loyola Medicine and the U.S. based Cook County Department of Homeland Security and Emergency Management collaborated, where Loyola Medicine trained police to use Narcan in the case of opioids overdose. Moreover, in 2017, Ontario government provided naloxone kits to police and fire departments in Ontario, Canada, to manage emergency case of opioid overdose. Government of Canada offered naloxone kits to all 61 police services and 447 fire departments in the Ontario province.

Key features of the study:

• This report provides an in-depth analysis of the global naloxone market , provides market size (US$ Million), and compound annual growth rate (CAGR%) for the forecast period (2022-2030), considering 2021 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrix for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategies adopted by the leading players
• It profiles leading players in the global naloxone market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments and strategies, and future plans
• Key companies covered as a part of this study include Viatris Inc., Opiant Pharmaceuticals, Akorn Operating Company LLC, Pfizer, Inc., Novartis AG, Indivior Plc., Emergent BioSolutions Inc., Amphastar Pharmaceuticals, Inc., Kern Pharma, S.L., Hikma Pharmaceuticals PLC, Mundipharma International Limited, and Kaleo, Inc.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decision regarding their future product launch, technology up-gradation, market expansion, and marketing tactics
• The global naloxone market report caters to various stakeholders in this industry including investors, suppliers, manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision making through various strategy matrices used in analyzing the global naloxone market

Detailed Segmentation:

• Global Naloxone Market, By Strength:
• 0 mg/0.1 ml and 4.0 mg/ml
• 1 mg/ml
• 4 mg/ml
• Others (Naloxone 2mg/2 ml vial, etc.)
• Global Naloxone Market, By Route of Administration:
• Intranasal
• Intramuscular/Subcutaneous
• Intravenous
• Global Naloxone Market, By Distribution Channel:
• Hospitals
• Public Hospitals
• Private Hospitals
• Clinics (Including Addiction Clinics)
• Retail Pharmacies
• Emergency Medical Services (EMS)
• Military Facilities
• Miscellaneous Facilities
• Online Pharmacies
• Others (long-term care facilities, etc.)
• Global Naloxone Market , By Region:
• North America
• By Country:
• U.S.
• Canada
• Latin America
• By Country:
• Brazil
• Mexico
• Argentina
• Rest of Latin America
• Europe
• By Country:
• U.K.
• Germany
• Italy
• Spain
• France
• Russia
• Rest of Europe
• Asia Pacific
• By Country
• China
• India
• Japan
• Australia
• South Korea
• ASEAN
• Rest of Asia Pacific
• Middle East
• By Country:
• GCC
• Israel
• Rest of Middle East
• Africa
• By Country/Region:
• South Africa
• Central Africa
• North Africa
• Company Profiles
• Viatris Inc.*
• Company Overview
• Product Portfolio
• Financial Performance
• Recent Developments/Updates
• Strategies
• Opiant Pharmaceuticals
• Akorn Operating Company LLC
• Pfizer, Inc.
• Novartis AG
• Indivior Plc.
• Emergent BioSolutions Inc.
• Amphastar Pharmaceuticals, Inc.
• Kern Pharma, S.L.
• Hikma Pharmaceuticals PLC
• Mundipharma International Limited
• Kaleo, Inc.

“*” marked represents similar segmentation in other categories in the respective section.